Get the Stockscreener App
36.34
5.73%
1.97
After Hours:
36.34
Crinetics Pharmaceuticals Inc stock is traded at $36.34, with a volume of 1.25M.
It is up +5.73% in the last 24 hours and down -16.25% over the past month.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
See More
Previous Close:
$34.37
Open:
$35.01
24h Volume:
1.25M
Relative Volume:
1.02
Market Cap:
$3.80B
Revenue:
$7.70M
Net Income/Loss:
$-465.32M
P/E Ratio:
-7.3494
EPS:
-4.9446
Net Cash Flow:
$-383.68M
1W Performance:
+0.80%
1M Performance:
-16.25%
6M Performance:
+1.25%
1Y Performance:
+3.62%
1-Day Range:
$34.89
$36.51
1-Week Range:
$33.40
$36.51
52-Week Range:
$24.10
$57.99
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
Name
Crinetics Pharmaceuticals Inc
Sector
Industry
Phone
858-450-6464
Address
6055 LUSK BLVD., SAN DIEGO, CA
Compare CRNX vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
36.34 | 3.60B | 7.70M | -465.32M | -383.68M | -4.9446 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-12-26 | Upgrade | Goldman | Neutral → Buy |
| Jul-10-25 | Initiated | Goldman | Neutral |
| Mar-25-25 | Initiated | Stifel | Buy |
| Feb-11-25 | Initiated | TD Cowen | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Peer Perform |
| Jan-22-25 | Upgrade | Jefferies | Hold → Buy |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Jan-16-24 | Initiated | Morgan Stanley | Overweight |
| Dec-21-23 | Initiated | Jefferies | Hold |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-31-23 | Initiated | Oppenheimer | Outperform |
| Apr-24-23 | Initiated | Piper Sandler | Overweight |
| Mar-30-23 | Initiated | Robert W. Baird | Outperform |
| Nov-30-21 | Initiated | JMP Securities | Mkt Outperform |
| Nov-23-21 | Initiated | Evercore ISI | Outperform |
| Jun-18-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-23-19 | Initiated | ROTH Capital | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Aug-13-18 | Initiated | JP Morgan | Neutral |
| Aug-13-18 | Initiated | Leerink Partners | Outperform |
| Aug-13-18 | Initiated | Piper Jaffray | Overweight |
View All
Crinetics Pharmaceuticals Inc Stock (CRNX) Latest News
Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B (XLV:NYSEARCA) - Seeking Alpha
Crinetics Pharmaceuticals (CRNX) Executive Resignation Announced - GuruFocus
Crinetics Pharma COO to step down - MSN
Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 4.3%Here's Why - MarketBeat
Crinetics Pharmaceuticals, Inc. Announces Resignation of Jeff Knight as Chief Development and Operating Officer, Effective on or About April 10, 2026 - marketscreener.com
Crinetics Pharmaceuticals, Inc. Files Form 8-K with SEC: Company Details, Stock Info, and Compliance Data (March 2026) - Minichart
Crinetics Pharmaceuticals chief development and operating officer to resign - Investing.com
Crinetics' Jeff Knight to Resign as Chief Development and Operating Officer - TradingView
Crinetics (NASDAQ: CRNX) COO-level executive Jeff Knight to resign by April 10, 2026 - Stock Titan
Q4 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Q2 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Q1 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Q3 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Stock Market Recap: Is Crinetics Pharmaceuticals Inc a stock for growth or value investorsTake Profit & Daily Stock Trend Watchlist - baoquankhu1.vn
Merger Talk: Whats the beta of Crinetics Pharmaceuticals Inc stockWeekly Market Report & Technical Entry and Exit Alerts - baoquankhu1.vn
JPMorgan Chase & Co. Acquires 926,765 Shares of Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
CRNX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Patterns Watch: What is the dividend yield of Crinetics Pharmaceuticals Inc2026 Retail & Weekly Top Gainers Alerts - baoquankhu1.vn
Crinetics Pharmaceuticals (NASDAQ:CRNX) Insider Stephen Betz Sells 10,612 Shares - MarketBeat
Crinetics Pharmaceuticals (NASDAQ:CRNX) CEO Sells $821,429.97 in Stock - MarketBeat
Crinetics Pharmaceuticals Insider Sold Shares Worth $821,513, According to a Recent SEC Filing - marketscreener.com
Crinetics Pharmaceuticals (CRNX) COO sells 9,911 shares for RSU taxes - Stock Titan
Crinetics (NASDAQ: CRNX) CSO sells shares to cover RSU tax - Stock Titan
Crinetics (CRNX) CEO discloses tax-related share sales under 10b5-1 plan - Stock Titan
CRNX (NASDAQ: CRNX) insider sells shares via 10b5-1 and option exercise - Stock Titan
Jim Cramer on Crinetics: “That’s a better spec than Aquestive” - MSN
CRNX Stock Price, Quote & Chart | CRINETICS PHARMACEUTICALS IN (NASDAQ:CRNX) - ChartMill
[144] Crinetics Pharmaceuticals, Inc. SEC Filing - Stock Titan
First Light Asset Management LLC Acquires 77,380 Shares of Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Crinetics Pharmaceuticals announces $350M proposed public offering - MSN
Farallon Capital Management LLC Increases Position in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Checkpoint Capital L.P. Purchases Shares of 260,000 Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Is Crinetics Pharmaceuticals (CRNX) Price Weakness Creating A Fresh Valuation Opportunity Now? - simplywall.st
Prosight Management LP Buys 30,561 Shares of Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Is Crinetics Pharmaceuticals (CRNX) Pricing Reflect Its Sharp Swings And DCF Upside Potential - Yahoo Finance
Coelho Rogerio Vivaldi Sells 5,000 Shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock - MarketBeat
Insider Sell: Coelho Vivaldi Sells 5,000 Shares of Crinetics Pha - GuruFocus
Crinetics Pharmaceuticals (CRNX) director sells 5,000 shares in planned trade - Stock Titan
Pier Capital LLC Has $3.12 Million Stake in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Recent Share Price Volatility - Sahm
Crinetics Advances Atumelnant: Phase 1 Study Completion Sets Up Next Clinical Catalyst for CRNX - The Globe and Mail
Income Plays: Can Crinetics Pharmaceuticals Inc stock outperform in a bear market2026 Rallies & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Systematic review on acromegaly therapies receives journal approval, Crinetics Pharmaceuticals announces - Traders Union
(CRNX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
WINTON GROUP Ltd Takes Position in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Levels Update: Is Crinetics Pharmaceuticals Inc a stock for growth or value investorsMarket Activity Recap & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Rafferty Asset Management LLC Decreases Stock Holdings in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Crinetics Pharmaceuticals Highlights Early PALSONIFY Sales, EU Milestone, and GPCR Pipeline at TD Cowen Conf. - Yahoo Finance
Should value investors consider Crinetics Pharmaceuticals Inc2026 Year in Review & Verified Momentum Stock Ideas - baoquankhu1.vn
Will Crinetics Pharmaceuticals Inc. stock attract more institutional investorsInsider Buying & High Win Rate Trade Alerts - Naître et grandir
Crinetics Pharmaceuticals, Inc. (CRNX)’ Oral Acromegaly Drug Nears FDA Decision After Strong Phase 3 Data - MSN
Crinetics Pharmaceuticals Inc Stock (CRNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):